Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein

Scandinavian Journal of Immunology

Volumn 55, Issue 5, 2002, Pages 484-492

  Budagian, V ^a   Nanni, P ^b   Lollini, P L ^b   Musiani, P ^c   Carlo, E D I ^c   Bulanova, E ^a   Paus, R ^d   Bulfone Paus, S ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G2B; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; GENETIC TRANSFECTION; IMMUNITY; LUNG METASTASIS; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

ADENOCARCINOMA; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GROWTH INHIBITORS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036254260     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2002.01081.x     Document Type: Article

References (36)

1. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ
2. Immunological properties of tumor cells genetically modified to secrete interleukin-2
3. Augmentation of local antitumor immunity in the liver by tumor vaccine modified to secrete murine interleukin 12
4. + T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity
5. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-2
6. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: The role of cytotoxic T lymphocytes
7. Priming in the brain, an immunologically privileged organ, elicits antitumor immunity
8. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells
9. Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: Differential effects on tumorigenicity and host response
10. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity
11. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma
12. Vaccination with tumor cells engineered to secrete interleukin 2-immunoglobulin G fusion protein induces tumor rejection
13. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity
14. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response
15. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1 beta converting enzyme cDNA
16. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs
17. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line
18. TS/A: A new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma
19. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice
20. Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells
21. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity
22. Vaccination with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant
23. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity
24. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity
25. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing
26. Cytokine-secreting tumor cell vaccines
27. Immunocytokines: A promising approach to cancer immunotherapy
28. Cancer vaccines
29. The biology and analysis of single disseminated tumour cells
30. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism
31. Shwartzman reaction
32. Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis
33. Phenotypic and functional characterization of lymphocytes that bind human microvascular endothelial cells in vitro. Evidence for preferential binding of natural killer cells
34. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis
35. Tumor endothelium selectively supports binding of IL-2-propagated tumor-infiltrating lymphocytes
36. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma